Antihemophilic Factor
Monoclate is a brand-name antihemophilic factor (recombinant) medication used to treat and prevent bleeding in patients with hemophilia A. It is administered via intravenous injection and provides a recombinant form of clotting factor VIII to replace the deficient or missing factor in affected individuals.
Monoclate is a recombinant factor VIII replacement therapy used to treat and prevent bleeding episodes in hemophilia A patients.
Key facts at a glance
- RxNorm
- 1718971
- Generic
- Monoclate
- Class
- brand-name
- Brands
- —
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- —
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Monoclate is indicated for the treatment and prevention of bleeding in patients with hemophilia A (congenital factor VIII deficiency). It may be used for on-demand treatment of bleeding episodes, routine prophylaxis to prevent bleeding, and perioperative management in patients undergoing surgery or dental procedures.
Monoclate contains recombinant human coagulation factor VIII (anti-hemophilic factor), which replaces the deficient or defective factor VIII in patients with hemophilia A. Factor VIII is essential for the intrinsic pathway of blood coagulation, enabling the formation of a stable fibrin clot to stop bleeding.
Monoclate should only be administered under the supervision of a qualified healthcare professional experienced in the management of hemophilia. Patients should be monitored for the development of factor VIII inhibitors, which can reduce treatment effectiveness. This product is contraindicated in patients with known hypersensitivity to any component of the formulation. Individual dosing is based on patient weight, factor VIII levels, and the severity of bleeding.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy